作者: Léonie Picard , Charlotte Bourgin , Frédérique Penault-Llorca , Marie Beguinot , Caroline Cornou
DOI: 10.1016/J.BULCAN.2019.04.003
关键词: Hyperthermic intraperitoneal chemotherapy 、 Internal medicine 、 Ovarian carcinoma 、 Context (language use) 、 Medicine 、 Peritoneal carcinomatosis 、 Oncology 、 Overall survival 、 First line
摘要: The results of PRODIGE 7 study demonstrate that the use HIPEC is not beneficial for patients in treatment colorectal carcinomatosis. Nevertheless, a recent published NewEnglandJournalofMedicine showed hyperthermic intraperitoneal chemotherapy (HIPEC) increased overall survival with ovarian peritoneal Although, emergence targeted therapies (anti-angiogenic agents, PARP-inhibitors, anti-PDL1) new standards first line or recurrence disease. In this general context, what potential interest carcinoma?